+Follow
安不理波波
Profile：To the Moon
9
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
安不理波波
2022-01-31
Come on!
EV Stocks Climbed in Premarket Trading
安不理波波
2021-06-16
Like
Toplines Before US Market Open on Wednesday
安不理波波
2021-06-16
6666666
Sorry, the original content has been removed
安不理波波
2021-06-15
6666
GSK, iTeos to develop cancer drug in up to $2 bln deal
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":3556192454279431,"uuid":"3556192454279431","gmtCreate":1593147307031,"gmtModify":1624026421916,"name":"安不理波波","pinyin":"ablbbanbulibobo","introduction":"","introductionEn":"","signature":"To the Moon","avatar":"https://static.tigerbbs.com/ee3973a5f6313415282b48ec8088d15d","hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","hatId":"ca_profile_frame_5b7Fd6","hatName":"","vip":1,"status":2,"fanSize":0,"headSize":9,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.12%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.81%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.67%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9093672314,"gmtCreate":1643626125146,"gmtModify":1676533837485,"author":{"id":"3556192454279431","authorId":"3556192454279431","name":"安不理波波","avatar":"https://static.tigerbbs.com/ee3973a5f6313415282b48ec8088d15d","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Come on! ","listText":"Come on! ","text":"Come on!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093672314","repostId":"1154394141","repostType":4,"repost":{"id":"1154394141","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1643621865,"share":"https://www.laohu8.com/m/news/1154394141?lang=&edition=full","pubTime":"2022-01-31 17:37","market":"us","language":"en","title":"EV Stocks Climbed in Premarket Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1154394141","media":"Tiger Newspress","summary":"Tesla, Nio, XPeng, and Li Auto rose between 2% and 3% in premarket trading.","content":"<html><head></head><body><p>Tesla, Nio, XPeng, and Li Auto rose between 2% and 3% in premarket trading.<img src=\"https://static.tigerbbs.com/55fdfc90b768682ad930a7fc093d1bbe\" tg-width=\"716\" tg-height=\"610\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV Stocks Climbed in Premarket Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV Stocks Climbed in Premarket Trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-31 17:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Tesla, Nio, XPeng, and Li Auto rose between 2% and 3% in premarket trading.<img src=\"https://static.tigerbbs.com/55fdfc90b768682ad930a7fc093d1bbe\" tg-width=\"716\" tg-height=\"610\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LI":"理想汽车","NIO":"蔚来","TSLA":"特斯拉"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1154394141","content_text":"Tesla, Nio, XPeng, and Li Auto rose between 2% and 3% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169435569,"gmtCreate":1623846804651,"gmtModify":1703821209627,"author":{"id":"3556192454279431","authorId":"3556192454279431","name":"安不理波波","avatar":"https://static.tigerbbs.com/ee3973a5f6313415282b48ec8088d15d","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/169435569","repostId":"1185341836","repostType":4,"repost":{"id":"1185341836","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623845207,"share":"https://www.laohu8.com/m/news/1185341836?lang=&edition=full","pubTime":"2021-06-16 20:06","market":"us","language":"en","title":"Toplines Before US Market Open on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1185341836","media":"Tiger Newspress","summary":"U.S. stock index futures were mostly flat on Wednesday ahead of the Federal Reserve's update on mone","content":"<p>U.S. stock index futures were mostly flat on Wednesday ahead of the Federal Reserve's update on monetary policy.</p>\n<p>Futures contracts tied to the Dow Jones Industrial Average were just 46 points lower. S&P 500 futures were largely flat, while Nasdaq 100 futures traded up by 0.1%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/33b560b1ab96b7a340369b24c17d6aa2\" tg-width=\"664\" tg-height=\"233\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:10</span></p>\n<p>The Fed has previously tried to assuage concerns that rising inflation would prompt it to tighten its ultra loose monetary policy, but data on Tuesday showing a jump in producer prices has again raised expectations the central bank could begin debating closing the taps at its meeting this week.</p>\n<p>The central bank's latest policy statement is expected to be released with fresh economic projections at 2 p.m. ET (1800 GMT).</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b>Oracle(ORCL) </b>– Oracleearned $1.54 per sharefor its latest quarter, beating the consensus estimate of $1.31 a share. The business software company's revenue topped estimates as well. The company forecast current-quarter profit below consensus, however, as it increases investment in its cloud computing operations. Its shares fell 4.7% in premarket trading.</p>\n<p><b>Roblox(RBLX) </b>– Roblox tumbled 7.7% in the premarket after it reported 43 million daily active users for May, up 28% compared to a year earlier but down from 43.3 million in April. Spending by users of the videogame platform was down slightly from a year earlier.</p>\n<p><b>Kindred Biosciences(KIN)</b> – The pet therapeutics company agreed to be acquired byElanco Animal Health(ELAN) for $9.25 per share, or $440 million. Kindred had closed at $6.34 Tuesday, and its stock surged 44.6% in the premarket.</p>\n<p><b>La-Z-Boy(LZB) </b>– La-Z-Boy reported quarterly earnings of 87 cents per share, compared to a consensus estimate of 74 cents a share. The company best known for its reclining chairs also reported better-than-expected revenue. La-Z-Boy said it was being impacted by supply chain issues and significant increases in raw materials prices. Its shares lost 2.3% in the premarket.</p>\n<p><b>H&R Block(HRB)</b> – H&R Block beat Street forecasts for both profit and revenue in its latest quarter, and the tax preparation firm also raised its quarterly dividend by 4% to 27 cents per share. Additionally, H&R Block is shifting the end of its fiscal year to June 30 from April 30, to better capture tax filing activity. H&R Block shares slid 1.1% in premarket action.</p>\n<p><b>EBay(EBAY)</b> – The online marketplace operator will sell its South Korean unit to retailer Shinsegae's E-Mart unit and website operator Naver for about $3.6 billion, according to local media reports. E-Mart acknowledged the talks but said that no deal had been finalized.</p>\n<p><b>General Motors(GM) </b>– GM reportedly plans to boost global spending on electric and autonomous vehicles by 30% from its most recent forecast to a total of $35 billion through 2025. People briefed on the plans told Reuters that the spending will include two additional U.S. battery plants.</p>\n<p><b>Johnson & Johnson(JNJ)</b> – The Food and Drug Administration cleared 15 million more doses of J&J's Covid-19 vaccine that had been produced at a Baltimore plant run byEmergent Biosolutions(EBS). That brings the total of cleared doses to 25 million. Earlier, the FDA had rejected 60 million doses produced at that plant, saying Emergent hadn't taken proper precautions to prevent cross-contamination with another production line that was producingAstraZeneca's(AZN) Covid vaccine.</p>\n<p><b>Southwest Airlines(LUV) </b>– Southwest suffered its second computer glitch in 24 hoursTuesday, with a system outage leading to the cancellation of about 500 flights and delaying many others.</p>\n<p><b>Dish Network(DISH) </b>– The satellite TV company was upgraded to \"buy\" from \"hold\" at Pivotal Research, which cited the potential for Dish's 5G wireless network. Dish rose 1.7% in the premarket.</p>\n<p><b>Apollo Global(APO) </b>– Apollo sold textbook and educational technology company McGraw Hill to private-equity firm Platinum Equity for $4.5 billion.</p>\n<p><b>Regeneron(REGN) </b>– The drugmaker'sCovid-19 antibody cocktailreduced deaths in patients who could not mount their own antibody response, according to a newly published British study.</p>\n<p><b>SoFi Technologies(SOFI) </b>– The financial services platform was rated \"buy\" in new coverage at Rosenblatt Securities, noting SoFi's \"powerful\" cost advantage over legacy banks. SoFi shares rose 2.1% in the premarket.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-16 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stock index futures were mostly flat on Wednesday ahead of the Federal Reserve's update on monetary policy.</p>\n<p>Futures contracts tied to the Dow Jones Industrial Average were just 46 points lower. S&P 500 futures were largely flat, while Nasdaq 100 futures traded up by 0.1%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/33b560b1ab96b7a340369b24c17d6aa2\" tg-width=\"664\" tg-height=\"233\" referrerpolicy=\"no-referrer\"><span>*Source From Tiger Trade, EST 08:10</span></p>\n<p>The Fed has previously tried to assuage concerns that rising inflation would prompt it to tighten its ultra loose monetary policy, but data on Tuesday showing a jump in producer prices has again raised expectations the central bank could begin debating closing the taps at its meeting this week.</p>\n<p>The central bank's latest policy statement is expected to be released with fresh economic projections at 2 p.m. ET (1800 GMT).</p>\n<p><b>Stocks making the biggest moves in the premarket:</b></p>\n<p><b>Oracle(ORCL) </b>– Oracleearned $1.54 per sharefor its latest quarter, beating the consensus estimate of $1.31 a share. The business software company's revenue topped estimates as well. The company forecast current-quarter profit below consensus, however, as it increases investment in its cloud computing operations. Its shares fell 4.7% in premarket trading.</p>\n<p><b>Roblox(RBLX) </b>– Roblox tumbled 7.7% in the premarket after it reported 43 million daily active users for May, up 28% compared to a year earlier but down from 43.3 million in April. Spending by users of the videogame platform was down slightly from a year earlier.</p>\n<p><b>Kindred Biosciences(KIN)</b> – The pet therapeutics company agreed to be acquired byElanco Animal Health(ELAN) for $9.25 per share, or $440 million. Kindred had closed at $6.34 Tuesday, and its stock surged 44.6% in the premarket.</p>\n<p><b>La-Z-Boy(LZB) </b>– La-Z-Boy reported quarterly earnings of 87 cents per share, compared to a consensus estimate of 74 cents a share. The company best known for its reclining chairs also reported better-than-expected revenue. La-Z-Boy said it was being impacted by supply chain issues and significant increases in raw materials prices. Its shares lost 2.3% in the premarket.</p>\n<p><b>H&R Block(HRB)</b> – H&R Block beat Street forecasts for both profit and revenue in its latest quarter, and the tax preparation firm also raised its quarterly dividend by 4% to 27 cents per share. Additionally, H&R Block is shifting the end of its fiscal year to June 30 from April 30, to better capture tax filing activity. H&R Block shares slid 1.1% in premarket action.</p>\n<p><b>EBay(EBAY)</b> – The online marketplace operator will sell its South Korean unit to retailer Shinsegae's E-Mart unit and website operator Naver for about $3.6 billion, according to local media reports. E-Mart acknowledged the talks but said that no deal had been finalized.</p>\n<p><b>General Motors(GM) </b>– GM reportedly plans to boost global spending on electric and autonomous vehicles by 30% from its most recent forecast to a total of $35 billion through 2025. People briefed on the plans told Reuters that the spending will include two additional U.S. battery plants.</p>\n<p><b>Johnson & Johnson(JNJ)</b> – The Food and Drug Administration cleared 15 million more doses of J&J's Covid-19 vaccine that had been produced at a Baltimore plant run byEmergent Biosolutions(EBS). That brings the total of cleared doses to 25 million. Earlier, the FDA had rejected 60 million doses produced at that plant, saying Emergent hadn't taken proper precautions to prevent cross-contamination with another production line that was producingAstraZeneca's(AZN) Covid vaccine.</p>\n<p><b>Southwest Airlines(LUV) </b>– Southwest suffered its second computer glitch in 24 hoursTuesday, with a system outage leading to the cancellation of about 500 flights and delaying many others.</p>\n<p><b>Dish Network(DISH) </b>– The satellite TV company was upgraded to \"buy\" from \"hold\" at Pivotal Research, which cited the potential for Dish's 5G wireless network. Dish rose 1.7% in the premarket.</p>\n<p><b>Apollo Global(APO) </b>– Apollo sold textbook and educational technology company McGraw Hill to private-equity firm Platinum Equity for $4.5 billion.</p>\n<p><b>Regeneron(REGN) </b>– The drugmaker'sCovid-19 antibody cocktailreduced deaths in patients who could not mount their own antibody response, according to a newly published British study.</p>\n<p><b>SoFi Technologies(SOFI) </b>– The financial services platform was rated \"buy\" in new coverage at Rosenblatt Securities, noting SoFi's \"powerful\" cost advantage over legacy banks. SoFi shares rose 2.1% in the premarket.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ORCL":"甲骨文",".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index","KIN":"Kindred Biosciences, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185341836","content_text":"U.S. stock index futures were mostly flat on Wednesday ahead of the Federal Reserve's update on monetary policy.\nFutures contracts tied to the Dow Jones Industrial Average were just 46 points lower. S&P 500 futures were largely flat, while Nasdaq 100 futures traded up by 0.1%.\n*Source From Tiger Trade, EST 08:10\nThe Fed has previously tried to assuage concerns that rising inflation would prompt it to tighten its ultra loose monetary policy, but data on Tuesday showing a jump in producer prices has again raised expectations the central bank could begin debating closing the taps at its meeting this week.\nThe central bank's latest policy statement is expected to be released with fresh economic projections at 2 p.m. ET (1800 GMT).\nStocks making the biggest moves in the premarket:\nOracle(ORCL) – Oracleearned $1.54 per sharefor its latest quarter, beating the consensus estimate of $1.31 a share. The business software company's revenue topped estimates as well. The company forecast current-quarter profit below consensus, however, as it increases investment in its cloud computing operations. Its shares fell 4.7% in premarket trading.\nRoblox(RBLX) – Roblox tumbled 7.7% in the premarket after it reported 43 million daily active users for May, up 28% compared to a year earlier but down from 43.3 million in April. Spending by users of the videogame platform was down slightly from a year earlier.\nKindred Biosciences(KIN) – The pet therapeutics company agreed to be acquired byElanco Animal Health(ELAN) for $9.25 per share, or $440 million. Kindred had closed at $6.34 Tuesday, and its stock surged 44.6% in the premarket.\nLa-Z-Boy(LZB) – La-Z-Boy reported quarterly earnings of 87 cents per share, compared to a consensus estimate of 74 cents a share. The company best known for its reclining chairs also reported better-than-expected revenue. La-Z-Boy said it was being impacted by supply chain issues and significant increases in raw materials prices. Its shares lost 2.3% in the premarket.\nH&R Block(HRB) – H&R Block beat Street forecasts for both profit and revenue in its latest quarter, and the tax preparation firm also raised its quarterly dividend by 4% to 27 cents per share. Additionally, H&R Block is shifting the end of its fiscal year to June 30 from April 30, to better capture tax filing activity. H&R Block shares slid 1.1% in premarket action.\nEBay(EBAY) – The online marketplace operator will sell its South Korean unit to retailer Shinsegae's E-Mart unit and website operator Naver for about $3.6 billion, according to local media reports. E-Mart acknowledged the talks but said that no deal had been finalized.\nGeneral Motors(GM) – GM reportedly plans to boost global spending on electric and autonomous vehicles by 30% from its most recent forecast to a total of $35 billion through 2025. People briefed on the plans told Reuters that the spending will include two additional U.S. battery plants.\nJohnson & Johnson(JNJ) – The Food and Drug Administration cleared 15 million more doses of J&J's Covid-19 vaccine that had been produced at a Baltimore plant run byEmergent Biosolutions(EBS). That brings the total of cleared doses to 25 million. Earlier, the FDA had rejected 60 million doses produced at that plant, saying Emergent hadn't taken proper precautions to prevent cross-contamination with another production line that was producingAstraZeneca's(AZN) Covid vaccine.\nSouthwest Airlines(LUV) – Southwest suffered its second computer glitch in 24 hoursTuesday, with a system outage leading to the cancellation of about 500 flights and delaying many others.\nDish Network(DISH) – The satellite TV company was upgraded to \"buy\" from \"hold\" at Pivotal Research, which cited the potential for Dish's 5G wireless network. Dish rose 1.7% in the premarket.\nApollo Global(APO) – Apollo sold textbook and educational technology company McGraw Hill to private-equity firm Platinum Equity for $4.5 billion.\nRegeneron(REGN) – The drugmaker'sCovid-19 antibody cocktailreduced deaths in patients who could not mount their own antibody response, according to a newly published British study.\nSoFi Technologies(SOFI) – The financial services platform was rated \"buy\" in new coverage at Rosenblatt Securities, noting SoFi's \"powerful\" cost advantage over legacy banks. SoFi shares rose 2.1% in the premarket.","news_type":1},"isVote":1,"tweetType":1,"viewCount":172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160356277,"gmtCreate":1623773314899,"gmtModify":1703819082282,"author":{"id":"3556192454279431","authorId":"3556192454279431","name":"安不理波波","avatar":"https://static.tigerbbs.com/ee3973a5f6313415282b48ec8088d15d","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"6666666","listText":"6666666","text":"6666666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160356277","repostId":"1185254731","repostType":4,"isVote":1,"tweetType":1,"viewCount":104,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184160801,"gmtCreate":1623689180303,"gmtModify":1704208861248,"author":{"id":"3556192454279431","authorId":"3556192454279431","name":"安不理波波","avatar":"https://static.tigerbbs.com/ee3973a5f6313415282b48ec8088d15d","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"6666","listText":"6666","text":"6666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/184160801","repostId":"2143782408","repostType":4,"repost":{"id":"2143782408","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623671890,"share":"https://www.laohu8.com/m/news/2143782408?lang=&edition=full","pubTime":"2021-06-14 19:58","market":"us","language":"en","title":"GSK, iTeos to develop cancer drug in up to $2 bln deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2143782408","media":"Reuters","summary":"June 14 (Reuters) - Britain's GlaxoSmithKline Plc has agreed to pay up to $2 billion to iTeos Therap","content":"<p>June 14 (Reuters) - Britain's GlaxoSmithKline Plc has agreed to pay up to $2 billion to <a href=\"https://laohu8.com/S/ITOS\">iTeos Therapeutics</a> Inc to develop and sell a potential cancer treatment together, the companies said on Monday.</p>\n<p>Boston-based iTeos will receive a $625 million upfront payment and is eligible to get up to $1.45 billion more if the programme meets certain development and commercial milestones.</p>\n<p>GlaxoSmithKline is under pressure to shore up its drug pipeline after a report that U.S. activist investor Elliott built up a significant stake in the company. The British drugmaker is also preparing to outline plans to split its consumer products business from its drug operations.</p>\n<p>The iTeos deal is to develop EOS-448, a monoclonal antibody using an anti-TIGIT agent which showed promise in early studies.</p>\n<p>Anti-TIGIT treatments are new experimental immunotherapies against certain cancer types. These treatments, including Roche's tiragolumab and Merck & Co's vibostolimab, are designed to deactivate a tumour's ability to evade the immune system.</p>\n<p>EOS-448 is currently being tested in an early-stage study in patients with advanced solid tumors.</p>\n<p>GSK and iTeos plan to start combination studies of EOS-448 with GSK's cancer drug dostarlimab in 2022.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK, iTeos to develop cancer drug in up to $2 bln deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK, iTeos to develop cancer drug in up to $2 bln deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-14 19:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>June 14 (Reuters) - Britain's GlaxoSmithKline Plc has agreed to pay up to $2 billion to <a href=\"https://laohu8.com/S/ITOS\">iTeos Therapeutics</a> Inc to develop and sell a potential cancer treatment together, the companies said on Monday.</p>\n<p>Boston-based iTeos will receive a $625 million upfront payment and is eligible to get up to $1.45 billion more if the programme meets certain development and commercial milestones.</p>\n<p>GlaxoSmithKline is under pressure to shore up its drug pipeline after a report that U.S. activist investor Elliott built up a significant stake in the company. The British drugmaker is also preparing to outline plans to split its consumer products business from its drug operations.</p>\n<p>The iTeos deal is to develop EOS-448, a monoclonal antibody using an anti-TIGIT agent which showed promise in early studies.</p>\n<p>Anti-TIGIT treatments are new experimental immunotherapies against certain cancer types. These treatments, including Roche's tiragolumab and Merck & Co's vibostolimab, are designed to deactivate a tumour's ability to evade the immune system.</p>\n<p>EOS-448 is currently being tested in an early-stage study in patients with advanced solid tumors.</p>\n<p>GSK and iTeos plan to start combination studies of EOS-448 with GSK's cancer drug dostarlimab in 2022.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ITOS":"iTeos Therapeutics","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143782408","content_text":"June 14 (Reuters) - Britain's GlaxoSmithKline Plc has agreed to pay up to $2 billion to iTeos Therapeutics Inc to develop and sell a potential cancer treatment together, the companies said on Monday.\nBoston-based iTeos will receive a $625 million upfront payment and is eligible to get up to $1.45 billion more if the programme meets certain development and commercial milestones.\nGlaxoSmithKline is under pressure to shore up its drug pipeline after a report that U.S. activist investor Elliott built up a significant stake in the company. The British drugmaker is also preparing to outline plans to split its consumer products business from its drug operations.\nThe iTeos deal is to develop EOS-448, a monoclonal antibody using an anti-TIGIT agent which showed promise in early studies.\nAnti-TIGIT treatments are new experimental immunotherapies against certain cancer types. These treatments, including Roche's tiragolumab and Merck & Co's vibostolimab, are designed to deactivate a tumour's ability to evade the immune system.\nEOS-448 is currently being tested in an early-stage study in patients with advanced solid tumors.\nGSK and iTeos plan to start combination studies of EOS-448 with GSK's cancer drug dostarlimab in 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":90,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9093672314,"gmtCreate":1643626125146,"gmtModify":1676533837485,"author":{"id":"3556192454279431","authorId":"3556192454279431","name":"安不理波波","avatar":"https://static.tigerbbs.com/ee3973a5f6313415282b48ec8088d15d","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Come on! ","listText":"Come on! ","text":"Come on!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9093672314","repostId":"1154394141","repostType":4,"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169435569,"gmtCreate":1623846804651,"gmtModify":1703821209627,"author":{"id":"3556192454279431","authorId":"3556192454279431","name":"安不理波波","avatar":"https://static.tigerbbs.com/ee3973a5f6313415282b48ec8088d15d","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/169435569","repostId":"1185341836","repostType":4,"isVote":1,"tweetType":1,"viewCount":172,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160356277,"gmtCreate":1623773314899,"gmtModify":1703819082282,"author":{"id":"3556192454279431","authorId":"3556192454279431","name":"安不理波波","avatar":"https://static.tigerbbs.com/ee3973a5f6313415282b48ec8088d15d","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"6666666","listText":"6666666","text":"6666666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160356277","repostId":"1185254731","repostType":4,"repost":{"id":"1185254731","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623764438,"share":"https://www.laohu8.com/m/news/1185254731?lang=&edition=full","pubTime":"2021-06-15 21:40","market":"us","language":"en","title":"ContextLogic gained as much as 10% a few minutes ago","url":"https://stock-news.laohu8.com/highlight/detail?id=1185254731","media":"Tiger Newspress","summary":"(June 15) ContextLogic gained as much as 10% a few minutes ago. ContextLogic gained nearly 6% for n","content":"<p>(June 15) ContextLogic gained as much as 10% a few minutes ago. ContextLogic gained nearly 6% for now.</p>\n<p><img src=\"https://static.tigerbbs.com/83f3eeb6c29b019970adceac690d15c3\" tg-width=\"663\" tg-height=\"440\" referrerpolicy=\"no-referrer\"></p>\n<p>ContextLogic signed a two-year partnership with an ecommerce platform,PrestaShop yesterday.</p>\n<p>More than 300,000 merchants and brands on the PrestaShop platform will be able to easily sell to millions of consumers on the Wish marketplace.</p>\n<p>Alan Small, Senior Business Development Manager for Wish in Europe said: “Wish serves millions of consumers around the world by providing high-quality products at affordable prices and a personalized, entertaining shopping experience. Partnering with PrestaShop will enable us to offer our consumers even more quality merchants and brands and to provide Prestashop merchants with a global platform to transact on.”</p>\n<p>Last week,the company's shares surged on attracting attention on the WallStreetBets Reddit forum.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ContextLogic gained as much as 10% a few minutes ago</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nContextLogic gained as much as 10% a few minutes ago\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-15 21:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(June 15) ContextLogic gained as much as 10% a few minutes ago. ContextLogic gained nearly 6% for now.</p>\n<p><img src=\"https://static.tigerbbs.com/83f3eeb6c29b019970adceac690d15c3\" tg-width=\"663\" tg-height=\"440\" referrerpolicy=\"no-referrer\"></p>\n<p>ContextLogic signed a two-year partnership with an ecommerce platform,PrestaShop yesterday.</p>\n<p>More than 300,000 merchants and brands on the PrestaShop platform will be able to easily sell to millions of consumers on the Wish marketplace.</p>\n<p>Alan Small, Senior Business Development Manager for Wish in Europe said: “Wish serves millions of consumers around the world by providing high-quality products at affordable prices and a personalized, entertaining shopping experience. Partnering with PrestaShop will enable us to offer our consumers even more quality merchants and brands and to provide Prestashop merchants with a global platform to transact on.”</p>\n<p>Last week,the company's shares surged on attracting attention on the WallStreetBets Reddit forum.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185254731","content_text":"(June 15) ContextLogic gained as much as 10% a few minutes ago. ContextLogic gained nearly 6% for now.\n\nContextLogic signed a two-year partnership with an ecommerce platform,PrestaShop yesterday.\nMore than 300,000 merchants and brands on the PrestaShop platform will be able to easily sell to millions of consumers on the Wish marketplace.\nAlan Small, Senior Business Development Manager for Wish in Europe said: “Wish serves millions of consumers around the world by providing high-quality products at affordable prices and a personalized, entertaining shopping experience. Partnering with PrestaShop will enable us to offer our consumers even more quality merchants and brands and to provide Prestashop merchants with a global platform to transact on.”\nLast week,the company's shares surged on attracting attention on the WallStreetBets Reddit forum.","news_type":1},"isVote":1,"tweetType":1,"viewCount":104,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":184160801,"gmtCreate":1623689180303,"gmtModify":1704208861248,"author":{"id":"3556192454279431","authorId":"3556192454279431","name":"安不理波波","avatar":"https://static.tigerbbs.com/ee3973a5f6313415282b48ec8088d15d","crmLevel":2,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"6666","listText":"6666","text":"6666","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/184160801","repostId":"2143782408","repostType":4,"repost":{"id":"2143782408","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1623671890,"share":"https://www.laohu8.com/m/news/2143782408?lang=&edition=full","pubTime":"2021-06-14 19:58","market":"us","language":"en","title":"GSK, iTeos to develop cancer drug in up to $2 bln deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2143782408","media":"Reuters","summary":"June 14 (Reuters) - Britain's GlaxoSmithKline Plc has agreed to pay up to $2 billion to iTeos Therap","content":"<p>June 14 (Reuters) - Britain's GlaxoSmithKline Plc has agreed to pay up to $2 billion to <a href=\"https://laohu8.com/S/ITOS\">iTeos Therapeutics</a> Inc to develop and sell a potential cancer treatment together, the companies said on Monday.</p>\n<p>Boston-based iTeos will receive a $625 million upfront payment and is eligible to get up to $1.45 billion more if the programme meets certain development and commercial milestones.</p>\n<p>GlaxoSmithKline is under pressure to shore up its drug pipeline after a report that U.S. activist investor Elliott built up a significant stake in the company. The British drugmaker is also preparing to outline plans to split its consumer products business from its drug operations.</p>\n<p>The iTeos deal is to develop EOS-448, a monoclonal antibody using an anti-TIGIT agent which showed promise in early studies.</p>\n<p>Anti-TIGIT treatments are new experimental immunotherapies against certain cancer types. These treatments, including Roche's tiragolumab and Merck & Co's vibostolimab, are designed to deactivate a tumour's ability to evade the immune system.</p>\n<p>EOS-448 is currently being tested in an early-stage study in patients with advanced solid tumors.</p>\n<p>GSK and iTeos plan to start combination studies of EOS-448 with GSK's cancer drug dostarlimab in 2022.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK, iTeos to develop cancer drug in up to $2 bln deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK, iTeos to develop cancer drug in up to $2 bln deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-14 19:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>June 14 (Reuters) - Britain's GlaxoSmithKline Plc has agreed to pay up to $2 billion to <a href=\"https://laohu8.com/S/ITOS\">iTeos Therapeutics</a> Inc to develop and sell a potential cancer treatment together, the companies said on Monday.</p>\n<p>Boston-based iTeos will receive a $625 million upfront payment and is eligible to get up to $1.45 billion more if the programme meets certain development and commercial milestones.</p>\n<p>GlaxoSmithKline is under pressure to shore up its drug pipeline after a report that U.S. activist investor Elliott built up a significant stake in the company. The British drugmaker is also preparing to outline plans to split its consumer products business from its drug operations.</p>\n<p>The iTeos deal is to develop EOS-448, a monoclonal antibody using an anti-TIGIT agent which showed promise in early studies.</p>\n<p>Anti-TIGIT treatments are new experimental immunotherapies against certain cancer types. These treatments, including Roche's tiragolumab and Merck & Co's vibostolimab, are designed to deactivate a tumour's ability to evade the immune system.</p>\n<p>EOS-448 is currently being tested in an early-stage study in patients with advanced solid tumors.</p>\n<p>GSK and iTeos plan to start combination studies of EOS-448 with GSK's cancer drug dostarlimab in 2022.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ITOS":"iTeos Therapeutics","GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143782408","content_text":"June 14 (Reuters) - Britain's GlaxoSmithKline Plc has agreed to pay up to $2 billion to iTeos Therapeutics Inc to develop and sell a potential cancer treatment together, the companies said on Monday.\nBoston-based iTeos will receive a $625 million upfront payment and is eligible to get up to $1.45 billion more if the programme meets certain development and commercial milestones.\nGlaxoSmithKline is under pressure to shore up its drug pipeline after a report that U.S. activist investor Elliott built up a significant stake in the company. The British drugmaker is also preparing to outline plans to split its consumer products business from its drug operations.\nThe iTeos deal is to develop EOS-448, a monoclonal antibody using an anti-TIGIT agent which showed promise in early studies.\nAnti-TIGIT treatments are new experimental immunotherapies against certain cancer types. These treatments, including Roche's tiragolumab and Merck & Co's vibostolimab, are designed to deactivate a tumour's ability to evade the immune system.\nEOS-448 is currently being tested in an early-stage study in patients with advanced solid tumors.\nGSK and iTeos plan to start combination studies of EOS-448 with GSK's cancer drug dostarlimab in 2022.","news_type":1},"isVote":1,"tweetType":1,"viewCount":90,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
